HC Wainwright & Co. Initiates Coverage On Magenta Therapeutics with Neutral Rating
HC Wainwright & Co. analyst Edward White initiates coverage on Magenta Therapeutics (NASDAQ:MGTA) with a Neutral rating.
BTIG Downgrades Magenta Therapeutics to Neutral
BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Athenex (NASDAQ:ATNX) stock moved upwards by 41.4% to $0.19 during Tuesday’s regular session. Trading volume for this…
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers OpGen (NASDAQ:OPGN) stock rose 69.6% to $0.21 during Tuesday’s pre-market session. The market value of their outstanding…
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers
Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting
Magenta Therapeutics Inc (NASDAQ:MGTA) highlighted updated data from the ongoing MGTA-117 Phase 1/2 dose-escalation trial at the American Society of Hematology…
Magenta Therapeutics Highlights Presentation Of MGTA-117 Clinical Data At ASH
– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to